Details for Patent: 10,682,376

Which drugs does patent 10,682,376 protect, and when does it expire?

Patent 10,682,376 protects VELPHORO and is included in one NDA.

Protection for VELPHORO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has ninety-three patent family members in thirty-four countries.

Summary for Patent: 10,682,376

Title:	Pharmaceutical compositions
Abstract:	Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
Inventor(s):	Weibel; Ludwig Daniel (Waldstatt, CH), Philipp; Erik (Arbon, CH)
Assignee:	Vifor Fresenius Medical Care Renal Pharma Ltd (St. Gallen, CH)
Application Number:	16/170,650
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 10,682,376

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vifor Fresenius	VELPHORO	ferric oxyhydroxide	TABLET, CHEWABLE;ORAL	205109-001	Nov 27, 2013		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 10,682,376

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	07120837	Nov 16, 2007

International Family Members for US Patent 10,682,376

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	069312
Australia	2008322963
Brazil	PI0820308
Canada	2700444
China	101861146
China	104688702